Migraine Drugs Market Size, Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities and Forecast Period
The migraine drugs market was
estimated to be worth USD 4.9 billion in 2023 and is expected to grow at a
compound annual growth rate (CAGR) of 4.4% from 2024 to 2034, reaching USD 7.6
billion. A variety of patient-specific therapy options are provided by migraine
medications. The market is increasing and sustainable since it is in line with
the healthcare industry.
A common and serious neurological condition, migraines are
characterized by strong, recurrent headaches that are frequently accompanied by
light and sound sensitivity, nausea, and vomiting. There are four phases that
migraine symptoms can go through, affecting both adults and children: prodrome,
aura, attack, and post-drome. Both preventive/prophylactic and acute abortive
medications are used in the therapy of migraines.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/migraine-drugs-market
GROWTH DRIVERS
The market is largely driven by the increasing prevalence
of migraines, which raises demand for efficient treatments. A JAMA Network
report states that overall, the incidence of migraines rose by 34% in men and
56% in women. Women in the 20–29 age group saw the largest increase, going from
600 to 1,000 new cases annually per 100,000 women. The NCBI reports that there
were an estimated 1.1 billion migraine cases in 2019 and that the prevalence of
migraines grew globally by 1.7% between 1990 and 2019. Males and those between
the ages of 10 and 14 showed the fastest growth in incidence, whereas females
and those between the ages of 20 and 24 had the highest prevalence and DALYs.
The WHO and Becker report that the expense of healthcare
increased to a record high of 10.7% in 2023 from 7.4% in 2022. Globally, the
insurer-reported cost trend is expected to average 9.9% in 2024, with some
regions experiencing a more significant increase. The substantial growth in
government health spending across all national income levels is responsible for
the surge in health spending to a record high of USD 9 trillion, or over 11% of
the world's gross domestic product.
MARKET
SEGMENTATION:
· By
Type- Acute/Abortive Treatment (Analgesic, Ergotamine, Triptans),
Preventive/P Treatment (Beta Blockers, Anti-serotonergic drugs,
anti-depressants, anticonvulsants, calcium channel blockers)
· By
Route of Administration- Oral, Injectable (Pre-filled Syringes, Vial)
· By
Distribution Channel- hospital pharmacies, retail pharmacies and online
pharmacies
· By
Region- North America, Europe, Asia Pacific, The Middle East and
Africa, South America
Global Key
Players:
· Novartis
AG
· AstraZeneca
· Amgen
Inc.
· Abbvie
· Glaxo
SmithKline plc
· Eli
Lilly and Compnany
· Abbott
Laboratories
· Teva
Pharmaceuticals Industries
· Pfizer
· Merck
& Co. Inc
· Bausch
Health Companies
· Janssen
Pharmaceutical Company
· Biohaven
Pharmaceutical Holding Company
· Endo
Pharmaceutical
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/migraine-drugs-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Comments
Post a Comment